May 06, 2026

Caris Life Sciences Launches Caris MI Clarity, the First and Only AI-Powered Test to Predict Both Early and Late Distant Recurrence Risk in Breast Cancer at the Time of Diagnosis

Caris MI Clarity leverages AI to transform how recurrence risk is understood and applied in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer IRVING, Texas, May 5, 2026 /PRNewswire/ -- Caris Life Sciences®...

recent articles

Support for the American Cancer Society’s national Hope Lodge program enables a home away from home for patients and their caregivers. Philadelphia – December 5, 2019 – Proscia, a leading provider of AI-enabled digital pathology...

The Ibex Second Read™ System for breast is now deployed at Maccabi's pathology institute, making it the first lab in the world to implement AI-powered cancer diagnostics for breast biopsies in its routine clinical practice TEL AVIV,...

MMI officially launches their latest imaging solution at the Digital Pathology congress in London, UK. The MMI CellScan is a new stand-alone system for Whole Slide Imaging. Researchers are now able to scan full resolution digital slides in...

Proving once again humor is the best medicine. Pathology parody on "A Million Dreams". Unfortunately, this is a million slides. Credits at the...

OR

platinum partners

gold partners

Silver Partners

Media Partners